1. Home
  2. TALO vs MLYS Comparison

TALO vs MLYS Comparison

Compare TALO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TALO

Talos Energy Inc.

HOLD

Current Price

$14.96

Market Cap

2.5B

Sector

Energy

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.62

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALO
MLYS
Founded
2011
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
TALO
MLYS
Price
$14.96
$23.62
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$18.00
$48.67
AVG Volume (30 Days)
1.6M
1.8M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
$1,780,070,000.00
N/A
Revenue This Year
$4.18
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.67
$12.59
52 Week High
$17.05
$47.65

Technical Indicators

Market Signals
Indicator
TALO
MLYS
Relative Strength Index (RSI) 48.32 37.91
Support Level $14.10 $22.42
Resistance Level $17.03 $31.29
Average True Range (ATR) 0.61 1.52
MACD -0.03 -0.56
Stochastic Oscillator 45.51 16.41

Price Performance

Historical Comparison
TALO
MLYS

About TALO Talos Energy Inc.

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: